Targeting both PI3K γ and PI3K δ with the selective inhibitor IPI-145 has shown a decrease in AML blast survival, secondary to the inhibition of AKT survival pathways, and also by affecting macrophage polarization [87,88]. The gene discussed is AKT1; the disease is acute myeloid leukemia.